CA3202212A1 - Indole derivatives useful in treating conditions associated with cgas - Google Patents
Indole derivatives useful in treating conditions associated with cgasInfo
- Publication number
- CA3202212A1 CA3202212A1 CA3202212A CA3202212A CA3202212A1 CA 3202212 A1 CA3202212 A1 CA 3202212A1 CA 3202212 A CA3202212 A CA 3202212A CA 3202212 A CA3202212 A CA 3202212A CA 3202212 A1 CA3202212 A1 CA 3202212A1
- Authority
- CA
- Canada
- Prior art keywords
- triazol
- methoxy
- chloro
- fluoro
- imidazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063128949P | 2020-12-22 | 2020-12-22 | |
| US63/128,949 | 2020-12-22 | ||
| PCT/IB2021/062029 WO2022137085A1 (en) | 2020-12-22 | 2021-12-20 | Indole derivatives useful in treating conditions associated with cgas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3202212A1 true CA3202212A1 (en) | 2022-06-30 |
Family
ID=79164465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3202212A Pending CA3202212A1 (en) | 2020-12-22 | 2021-12-20 | Indole derivatives useful in treating conditions associated with cgas |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12404261B2 (https=) |
| EP (1) | EP4267564A1 (https=) |
| JP (1) | JP2024502258A (https=) |
| KR (1) | KR20230124665A (https=) |
| CN (1) | CN116635382A (https=) |
| AR (1) | AR124443A1 (https=) |
| AU (1) | AU2021404953A1 (https=) |
| CA (1) | CA3202212A1 (https=) |
| CL (1) | CL2023001859A1 (https=) |
| CO (1) | CO2023007954A2 (https=) |
| CR (1) | CR20230282A (https=) |
| DO (1) | DOP2023000129A (https=) |
| EC (1) | ECSP23045506A (https=) |
| IL (1) | IL303913A (https=) |
| JO (1) | JOP20230146A1 (https=) |
| MX (1) | MX2023007467A (https=) |
| PE (1) | PE20240229A1 (https=) |
| PY (1) | PY21111338A (https=) |
| SA (1) | SA523441335B1 (https=) |
| TW (1) | TW202241873A (https=) |
| UY (1) | UY39579A (https=) |
| WO (1) | WO2022137085A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202132316A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2023235809A1 (en) * | 2022-06-02 | 2023-12-07 | Eli Lilly And Company | Cgas inhibitors |
| TW202430156A (zh) | 2022-10-18 | 2024-08-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 化合物 |
| KR20250131845A (ko) * | 2022-12-20 | 2025-09-03 | 벤투스 테라퓨틱스 유에스 인코포레이티드 | 고리형 gmp-amp 생성효소 억제제로서 싸이아다이아졸 유도체 및 이의 용도 |
| AU2023409125A1 (en) | 2022-12-21 | 2025-06-26 | Eli Lilly And Company | Azepino[4,5-b]indolone cgas inhibitors |
| TW202440093A (zh) * | 2023-03-06 | 2024-10-16 | 香港商英矽智能科技知識產權有限公司 | Cdk8/19雙重抑制劑及其使用方法 |
| WO2025215082A1 (en) * | 2024-04-11 | 2025-10-16 | Glaxosmithkline Intellectual Property Development Limited | Fused azines for the treatment of inflammatory diseases |
| WO2025231011A1 (en) * | 2024-05-01 | 2025-11-06 | Omniab, Inc. | Heteroarylindole inhibitors of apol-1 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20040874A1 (it) * | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
| EA200901212A1 (ru) * | 2007-03-29 | 2010-04-30 | Новартис Аг | 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний |
| MX2010014394A (es) | 2008-06-20 | 2011-05-19 | Rottapharm Spa | Derivados de 6-1h-imidazo-quinazolina y quinolinas, nuevos inhibidores de monoamina oxidasa y ligandos del receptor de imidazolina. |
| US9096579B2 (en) | 2012-04-20 | 2015-08-04 | Boehringer Ingelheim International Gmbh | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments |
| EP2934598B1 (en) * | 2012-12-19 | 2018-04-18 | Board Of Regents, The University Of Texas System | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway |
| US9840533B2 (en) * | 2013-04-29 | 2017-12-12 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| WO2016103037A1 (en) | 2014-12-22 | 2016-06-30 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| SG11202002218VA (en) | 2017-09-15 | 2020-04-29 | Aduro Biotech Inc | Pyrazolopyrimidinone compounds and uses thereof |
| BR112020016008A2 (pt) * | 2018-02-05 | 2020-12-15 | The Rockefeller University | Composto, método para inibir uma resposta inflamatória em um paciente, método para inibir inflamação em um paciente, método para inibir expressão de interferon ativada por dsdna em um mamífero, método para tratar metástase de câncer em um paciente e formulação farmacêutica |
| MX2020008265A (es) * | 2018-02-16 | 2020-09-21 | UCB Biopharma SRL | Derivados farmaceuticos del anillo heterobiciclico 6,5. |
| WO2020123422A1 (en) | 2018-12-10 | 2020-06-18 | Aduro Biotech, Inc. | Imidazopyridazinone compounds and uses thereof |
| CA3125626A1 (en) | 2019-01-04 | 2020-07-09 | Bellbrook Labs, Llc | Inhibitors of cgas activity as therapeutic agents |
| US12522603B2 (en) | 2019-03-13 | 2026-01-13 | The Rockefeller University | Inhibitors of gas for treating autoinflammatory diseases and cancer metastasis |
| WO2021209475A1 (en) | 2020-04-16 | 2021-10-21 | F. Hoffmann-La Roche Ag | Sulfamoylamide derivatives |
| US20230192623A1 (en) | 2020-04-16 | 2023-06-22 | Hoffmann-La Roche Inc. | Indazole Derivatives |
| JP2023522327A (ja) | 2020-04-16 | 2023-05-30 | エフ． ホフマン－ラ ロシュ アーゲー | ベンズイミダゾール誘導体 |
| WO2021209473A1 (en) | 2020-04-16 | 2021-10-21 | F. Hoffmann-La Roche Ag | Biphenyl derivatives |
| US20230348398A1 (en) | 2020-04-16 | 2023-11-02 | Hoffmann-La Roche Inc. | Benzimidazole derivatives |
| KR20230062845A (ko) | 2020-09-03 | 2023-05-09 | 이뮨센서 테라퓨틱스, 인코포레이티드 | 퀴놀린 cgas 길항제 화합물 |
| AU2021349249A1 (en) | 2020-09-24 | 2023-04-13 | Ventus Therapeutics U.S., Inc. | Pyrido(4,3-b)indole derivatives and their use as pharmaceuticals |
-
2021
- 2021-12-20 WO PCT/IB2021/062029 patent/WO2022137085A1/en not_active Ceased
- 2021-12-20 CR CR20230282A patent/CR20230282A/es unknown
- 2021-12-20 JP JP2023537694A patent/JP2024502258A/ja active Pending
- 2021-12-20 AU AU2021404953A patent/AU2021404953A1/en active Pending
- 2021-12-20 US US17/645,071 patent/US12404261B2/en active Active
- 2021-12-20 UY UY0001039579A patent/UY39579A/es unknown
- 2021-12-20 PY PY202121111338A patent/PY21111338A/es unknown
- 2021-12-20 KR KR1020237024854A patent/KR20230124665A/ko active Pending
- 2021-12-20 AR ARP210103590A patent/AR124443A1/es unknown
- 2021-12-20 CA CA3202212A patent/CA3202212A1/en active Pending
- 2021-12-20 PE PE2023001937A patent/PE20240229A1/es unknown
- 2021-12-20 EP EP21834940.5A patent/EP4267564A1/en active Pending
- 2021-12-20 TW TW110147655A patent/TW202241873A/zh unknown
- 2021-12-20 IL IL303913A patent/IL303913A/en unknown
- 2021-12-20 MX MX2023007467A patent/MX2023007467A/es unknown
- 2021-12-20 CN CN202180079723.3A patent/CN116635382A/zh active Pending
-
2023
- 2023-06-20 JO JOJO/P/2023/0146A patent/JOP20230146A1/ar unknown
- 2023-06-20 CO CONC2023/0007954A patent/CO2023007954A2/es unknown
- 2023-06-20 CL CL2023001859A patent/CL2023001859A1/es unknown
- 2023-06-20 EC ECSENADI202345506A patent/ECSP23045506A/es unknown
- 2023-06-21 DO DO2023000129A patent/DOP2023000129A/es unknown
- 2023-06-21 SA SA523441335A patent/SA523441335B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023007467A (es) | 2023-07-04 |
| KR20230124665A (ko) | 2023-08-25 |
| EP4267564A1 (en) | 2023-11-01 |
| DOP2023000129A (es) | 2023-07-16 |
| AU2021404953A9 (en) | 2024-02-08 |
| AU2021404953A1 (en) | 2023-06-22 |
| TW202241873A (zh) | 2022-11-01 |
| WO2022137085A1 (en) | 2022-06-30 |
| JP2024502258A (ja) | 2024-01-18 |
| CR20230282A (es) | 2023-07-12 |
| AR124443A1 (es) | 2023-03-29 |
| CL2023001859A1 (es) | 2024-02-09 |
| SA523441335B1 (ar) | 2025-04-20 |
| CN116635382A (zh) | 2023-08-22 |
| IL303913A (en) | 2023-08-01 |
| US20230085472A1 (en) | 2023-03-16 |
| ECSP23045506A (es) | 2023-07-31 |
| PY21111338A (es) | 2022-07-18 |
| UY39579A (es) | 2022-07-29 |
| PE20240229A1 (es) | 2024-02-16 |
| US12404261B2 (en) | 2025-09-02 |
| JOP20230146A1 (ar) | 2023-06-20 |
| CO2023007954A2 (es) | 2023-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3202212A1 (en) | Indole derivatives useful in treating conditions associated with cgas | |
| JP7487421B2 (ja) | Ｐｒｍｔ５阻害剤 | |
| AU2019203122B2 (en) | Cot modulators and methods of use thereof | |
| AU2017232610B2 (en) | Compounds and methods for kinase modulation and indications therefore | |
| CA2694401C (en) | Polycyclic compound | |
| KR101959590B1 (ko) | c-KIT 키나제 억제제로서의 화합물 및 조성물 | |
| JP2018521025A (ja) | Ｔｎｆ活性のモジュレーターとしてのベンゾオキサジノン誘導体およびその類似体 | |
| EP3843842A1 (en) | Cardiac sarcomere inhibitors | |
| TW201247673A (en) | Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders | |
| CA2942997A1 (en) | Heteroaryl syk inhibitors | |
| AU2016322813A1 (en) | Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors | |
| EA028626B1 (ru) | БЕНЗИМИДАЗОЛЫ, МОДУЛИРУЮЩИЕ TNF-α | |
| AU2013249041A1 (en) | Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an HIV infection | |
| EP4267571A1 (en) | Pyrrolo[3,2-b]pyridine derivatives useful in treating conditions associated with cgas | |
| KR20160086930A (ko) | 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도 | |
| WO2023091726A1 (en) | Inhibitors of cyclin‑dependent kinase 12 (cdk12) | |
| TWI829481B (zh) | 雙環吲唑糖皮質素受體拮抗劑 | |
| JP7713461B2 (ja) | 大環状ｒｉｐ２－キナーゼ阻害剤 | |
| WO2016090296A1 (en) | Heterocyclic compounds as biogenic amine transport modulators | |
| AU2022364646B2 (en) | SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF | |
| EP3265464A1 (en) | Triazolopyridine compounds and methods of use thereof | |
| TWI888920B (zh) | 苯基取代的二氫萘啶類化合物及其製備與用途 | |
| TWI889173B (zh) | 含苯基取代的二氫萘啶類化合物的藥物製劑與用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241120 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241120 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241120 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251118 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251118 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251202 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251202 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260127 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260128 |